| pubmed-article:12028899 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12028899 | lifeskim:mentions | umls-concept:C0019196 | lld:lifeskim |
| pubmed-article:12028899 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:12028899 | lifeskim:mentions | umls-concept:C0021734 | lld:lifeskim |
| pubmed-article:12028899 | lifeskim:mentions | umls-concept:C1623038 | lld:lifeskim |
| pubmed-article:12028899 | lifeskim:mentions | umls-concept:C0600558 | lld:lifeskim |
| pubmed-article:12028899 | lifeskim:mentions | umls-concept:C1096776 | lld:lifeskim |
| pubmed-article:12028899 | pubmed:issue | 17 | lld:pubmed |
| pubmed-article:12028899 | pubmed:dateCreated | 2002-5-24 | lld:pubmed |
| pubmed-article:12028899 | pubmed:abstractText | Although standard dose interferon (IFN) is successful in only 5% of patients with compensated hepatitis C virus (HCV)-related cirrhosis, it has been suggested that this therapy might decrease the risk of complications or the incidence of hepatocellular carcinoma. Based on HCV kinetics, daily IFN may improve response rates. | lld:pubmed |
| pubmed-article:12028899 | pubmed:language | spa | lld:pubmed |
| pubmed-article:12028899 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12028899 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12028899 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12028899 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12028899 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12028899 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12028899 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12028899 | pubmed:month | May | lld:pubmed |
| pubmed-article:12028899 | pubmed:issn | 0025-7753 | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:BrugueraMique... | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:CasanovasTere... | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:TorresMiquelM | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:PlanasRamonR | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:QuerJuan... | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:EnríquezJaime... | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:BarreraJosep... | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:DalmauBlaiB | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:ViverJosep... | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:BoadasJaumeJ | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:SolàRicartR | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:DurándezRosaR | lld:pubmed |
| pubmed-article:12028899 | pubmed:author | pubmed-author:RichartCristó... | lld:pubmed |
| pubmed-article:12028899 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12028899 | pubmed:day | 11 | lld:pubmed |
| pubmed-article:12028899 | pubmed:volume | 118 | lld:pubmed |
| pubmed-article:12028899 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12028899 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12028899 | pubmed:pagination | 641-4 | lld:pubmed |
| pubmed-article:12028899 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:12028899 | pubmed:meshHeading | pubmed-meshheading:12028899... | lld:pubmed |
| pubmed-article:12028899 | pubmed:meshHeading | pubmed-meshheading:12028899... | lld:pubmed |
| pubmed-article:12028899 | pubmed:meshHeading | pubmed-meshheading:12028899... | lld:pubmed |
| pubmed-article:12028899 | pubmed:meshHeading | pubmed-meshheading:12028899... | lld:pubmed |
| pubmed-article:12028899 | pubmed:meshHeading | pubmed-meshheading:12028899... | lld:pubmed |
| pubmed-article:12028899 | pubmed:meshHeading | pubmed-meshheading:12028899... | lld:pubmed |
| pubmed-article:12028899 | pubmed:meshHeading | pubmed-meshheading:12028899... | lld:pubmed |
| pubmed-article:12028899 | pubmed:meshHeading | pubmed-meshheading:12028899... | lld:pubmed |
| pubmed-article:12028899 | pubmed:meshHeading | pubmed-meshheading:12028899... | lld:pubmed |
| pubmed-article:12028899 | pubmed:meshHeading | pubmed-meshheading:12028899... | lld:pubmed |
| pubmed-article:12028899 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12028899 | pubmed:articleTitle | [Induction therapy with interferon alfa-2a in compensated hepatitis C virus-related cirrhosis. Randomized, multicenter study]. | lld:pubmed |
| pubmed-article:12028899 | pubmed:affiliation | Hospital Universitari Germans Trias i Pujol. Badalona. BArcelona. Spain. rplanas@ns.hugtip.scs.es | lld:pubmed |
| pubmed-article:12028899 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12028899 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12028899 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:12028899 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:12028899 | pubmed:publicationType | Multicenter Study | lld:pubmed |
